Consequently, detecting CNV deletions of exon 22 in BRCA1 and exon 27 in BRCA2 is critical for guiding therapeutic strategies for advanced prostate cancer [4,11,17]. This evidence concerns the gene BRCA1 and Familial prostate cancer.